{"transactions":[{"id":677412,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":20360,"kind":"person","name":"Azoy Alexander","position":1,"cik":"0001771961","reported_name":"Azoy Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-08-24T21:52:18.000Z","date":"2026-08-21","kind":"exercise","planned":true,"acquired":false,"shares":2827,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option becomes exercisable in 48 equal monthly installments after January 1, 2024, subject to the Reporting Person's continued service to the Company."}],"balance_after":3073,"derivative":{"exercise_price":15.44,"expiration_date":"2034-01-22","underlying":"Common Stock","underlying_shares":2827},"source":{"system":"sec-edgar","filing":"0001771961-26-000006","document":"wk-form4_1787608336.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000177196126000006/wk-form4_1787608336.xml","form_type":"4"}},{"id":677411,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":20360,"kind":"person","name":"Azoy Alexander","position":1,"cik":"0001771961","reported_name":"Azoy Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2026-08-24T21:52:18.000Z","date":"2026-08-21","kind":"sale","planned":true,"acquired":false,"shares":2827,"price":30,"value":84810.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes the unvested portion of the Reporting Person's RSU grants."}],"balance_after":39581,"source":{"system":"sec-edgar","filing":"0001771961-26-000006","document":"wk-form4_1787608336.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000177196126000006/wk-form4_1787608336.xml","form_type":"4"}},{"id":677410,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":20360,"kind":"person","name":"Azoy Alexander","position":1,"cik":"0001771961","reported_name":"Azoy Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2026-08-24T21:52:18.000Z","date":"2026-08-21","kind":"exercise","planned":true,"acquired":true,"shares":2827,"price":15.44,"value":43648.88,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes the unvested portion of the Reporting Person's RSU grants."}],"balance_after":42408,"source":{"system":"sec-edgar","filing":"0001771961-26-000006","document":"wk-form4_1787608336.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000177196126000006/wk-form4_1787608336.xml","form_type":"4"}},{"id":757084,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":20360,"kind":"person","name":"Azoy Alexander","position":1,"cik":"0001771961","reported_name":"Azoy Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2026-06-01T23:23:58.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":2562,"price":25.7704,"value":66023.7648,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Consists of 2,562 shares purchased on 5/29/2026 through the Company's Employee Stock Purchase Plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.67 to $25.90, inclusive. The reporting person undertakes to\nprovide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price\nwithin the ranges set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes the unvested portion of the Reporting Person's RSU grants."}],"balance_after":39581,"source":{"system":"sec-edgar","filing":"0001771961-26-000004","document":"wk-form4_1780356235.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000177196126000004/wk-form4_1780356235.xml","form_type":"4"}},{"id":931186,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":20360,"kind":"person","name":"Azoy Alexander","position":1,"cik":"0001771961","reported_name":"Azoy Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-27T01:21:23.000Z","date":"2026-01-23","kind":"grant","planned":false,"acquired":true,"shares":14050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to the Reporting Person's continued service to the Company."}],"balance_after":14050,"derivative":{"exercise_price":22.13,"expiration_date":"2036-01-22","underlying":"Common Stock","underlying_shares":14050},"source":{"system":"sec-edgar","filing":"0001771961-26-000002","document":"wk-form4_1769476880.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000177196126000002/wk-form4_1769476880.xml","form_type":"4"}},{"id":931185,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":20360,"kind":"person","name":"Azoy Alexander","position":1,"cik":"0001771961","reported_name":"Azoy Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2026-01-27T01:21:23.000Z","date":"2026-01-23","kind":"grant","planned":false,"acquired":true,"shares":21050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2026, subject to the Reporting Person's continued service to the Company."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes the unvested portion of the Reporting Person's RSU grants."}],"balance_after":39581,"source":{"system":"sec-edgar","filing":"0001771961-26-000002","document":"wk-form4_1769476880.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000177196126000002/wk-form4_1769476880.xml","form_type":"4"}},{"id":963191,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":20360,"kind":"person","name":"Azoy Alexander","position":1,"cik":"0001771961","reported_name":"Azoy Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2025-12-18T22:35:29.000Z","date":"2025-12-18","kind":"sale","planned":true,"acquired":false,"shares":4343,"price":22.2458,"value":96613.5094,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 6, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.90 to $22.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes the unvested portion of the reporting person's RSU grants."}],"balance_after":18531,"source":{"system":"sec-edgar","filing":"0001771961-25-000014","document":"wk-form4_1766097326.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000177196125000014/wk-form4_1766097326.xml","form_type":"4"}},{"id":963190,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":20360,"kind":"person","name":"Azoy Alexander","position":1,"cik":"0001771961","reported_name":"Azoy Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2025-12-18T22:35:29.000Z","date":"2025-12-17","kind":"sale","planned":true,"acquired":false,"shares":2113,"price":22.1595,"value":46823.0235,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold by the issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the\ndate of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on May 22, 2025, and does not represent a discretionary trade by the reporting\nperson."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.92 to $22.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes the unvested portion of the reporting person's RSU grants."}],"balance_after":22874,"source":{"system":"sec-edgar","filing":"0001771961-25-000014","document":"wk-form4_1766097326.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000177196125000014/wk-form4_1766097326.xml","form_type":"4"}},{"id":963189,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":20360,"kind":"person","name":"Azoy Alexander","position":1,"cik":"0001771961","reported_name":"Azoy Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2025-12-18T22:35:29.000Z","date":"2025-12-16","kind":"sale","planned":true,"acquired":false,"shares":2376,"price":21.8843,"value":51997.0968,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold by the issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the\ndate of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on May 22, 2025, and does not represent a discretionary trade by the reporting\nperson."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.42 to $22.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the\nranges set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes the unvested portion of the reporting person's RSU grants."}],"balance_after":24987,"source":{"system":"sec-edgar","filing":"0001771961-25-000014","document":"wk-form4_1766097326.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000177196125000014/wk-form4_1766097326.xml","form_type":"4"}},{"id":985117,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":20360,"kind":"person","name":"Azoy Alexander","position":1,"cik":"0001771961","reported_name":"Azoy Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-12-01T23:09:43.000Z","date":"2025-11-26","kind":"exercise","planned":true,"acquired":false,"shares":1900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option becomes exercisable in 48 equal monthly installments after January 1, 2025, subject to the Reporting Person's continued service to the Company."}],"balance_after":9500,"derivative":{"exercise_price":13.33,"expiration_date":"2035-01-22","underlying":"Common Stock","underlying_shares":1900},"source":{"system":"sec-edgar","filing":"0001771961-25-000009","document":"wk-form4_1764630580.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000177196125000009/wk-form4_1764630580.xml","form_type":"4"}},{"id":985116,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":20360,"kind":"person","name":"Azoy Alexander","position":1,"cik":"0001771961","reported_name":"Azoy Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2025-12-01T23:09:43.000Z","date":"2025-11-26","kind":"sale","planned":true,"acquired":false,"shares":1900,"price":26,"value":49400.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":27363,"source":{"system":"sec-edgar","filing":"0001771961-25-000009","document":"wk-form4_1764630580.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000177196125000009/wk-form4_1764630580.xml","form_type":"4"}},{"id":985115,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":20360,"kind":"person","name":"Azoy Alexander","position":1,"cik":"0001771961","reported_name":"Azoy Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2025-12-01T23:09:43.000Z","date":"2025-11-26","kind":"exercise","planned":true,"acquired":true,"shares":1900,"price":13.33,"value":25327.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":29263,"source":{"system":"sec-edgar","filing":"0001771961-25-000009","document":"wk-form4_1764630580.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000177196125000009/wk-form4_1764630580.xml","form_type":"4"}},{"id":1030581,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":20360,"kind":"person","name":"Azoy Alexander","position":1,"cik":"0001771961","reported_name":"Azoy Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2025-09-30T22:59:03.000Z","date":"2025-09-29","kind":"sale","planned":true,"acquired":false,"shares":2831,"price":13,"value":36803.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 6, 2025."}],"balance_after":27363,"source":{"system":"sec-edgar","filing":"0001771961-25-000006","document":"wk-form4_1759273140.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000177196125000006/wk-form4_1759273140.xml","form_type":"4"}},{"id":1046835,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":20360,"kind":"person","name":"Azoy Alexander","position":1,"cik":"0001771961","reported_name":"Azoy Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2025-09-05T23:48:11.000Z","date":"2025-09-05","kind":"sale","planned":true,"acquired":false,"shares":1579,"price":11.8797,"value":18758.0463,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of 1,579 shares purchased on 5/30/2025 through the Company's Employee Stock Purchase Plan."},{"field":"shares","element":"transactionShares","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 6, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.55 to $12.22, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":30194,"source":{"system":"sec-edgar","filing":"0001771961-25-000003","document":"wk-form4_1757116088.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000177196125000003/wk-form4_1757116088.xml","form_type":"4"}},{"id":1294496,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":20360,"kind":"person","name":"Azoy Alexander","position":1,"cik":"0001771961","reported_name":"Azoy Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-27T21:30:12.000Z","date":"2025-01-23","kind":"grant","planned":false,"acquired":true,"shares":11400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option becomes exercisable in 48 equal monthly installments after January 1, 2025, subject to the Reporting Person's continued service to the Company."}],"balance_after":11400,"derivative":{"exercise_price":13.33,"expiration_date":"2035-01-22","underlying":"Common Stock","underlying_shares":11400},"source":{"system":"sec-edgar","filing":"0001724521-25-000016","document":"wk-form4_1738013405.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000172452125000016/wk-form4_1738013405.xml","form_type":"4"}},{"id":1294495,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":20360,"kind":"person","name":"Azoy Alexander","position":1,"cik":"0001771961","reported_name":"Azoy Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2025-01-27T21:30:12.000Z","date":"2025-01-23","kind":"grant","planned":false,"acquired":true,"shares":17100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2025, subject to the Reporting Person's continued service to the Company."}],"balance_after":30194,"source":{"system":"sec-edgar","filing":"0001724521-25-000016","document":"wk-form4_1738013405.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000172452125000016/wk-form4_1738013405.xml","form_type":"4"}},{"id":1324162,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":20360,"kind":"person","name":"Azoy Alexander","position":1,"cik":"0001771961","reported_name":"Azoy Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-12-20T21:06:34.000Z","date":"2024-12-19","kind":"disposition_to_issuer","planned":true,"acquired":false,"shares":3007,"price":15.17,"value":45616.19,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2024."}],"balance_after":13094,"source":{"system":"sec-edgar","filing":"0001724521-24-000187","document":"wk-form4_1734728787.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000172452124000187/wk-form4_1734728787.xml","form_type":"4"}},{"id":1328850,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":20360,"kind":"person","name":"Azoy Alexander","position":1,"cik":"0001771961","reported_name":"Azoy Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-12-18T01:36:07.000Z","date":"2024-12-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":2969,"price":16.08,"value":47741.52,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the \"net settlement\" by the Issuer of RSUs previously granted to the reporting person in order to satisfy the applicable tax withholding obligations in connection with the vesting and settlement of such RSUs."}],"balance_after":16101,"source":{"system":"sec-edgar","filing":"0001724521-24-000179","document":"wk-form4_1734485761.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000172452124000179/wk-form4_1734485761.xml","form_type":"4"}},{"id":1343004,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":20360,"kind":"person","name":"Azoy Alexander","position":1,"cik":"0001771961","reported_name":"Azoy Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-12-04T21:10:55.000Z","date":"2024-12-02","kind":"sale","planned":true,"acquired":false,"shares":201,"price":15.32,"value":3079.32,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2024."},{"field":"shares","element":"transactionShares","label":"F2","text":"Consists of 201 shares purchased on 11/29/2024 through the Company's Employee Stock Purchase Plan."}],"balance_after":19070,"source":{"system":"sec-edgar","filing":"0001724521-24-000162","document":"wk-form4_1733346648.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000172452124000162/wk-form4_1733346648.xml","form_type":"4"}},{"id":1432579,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":20360,"kind":"person","name":"Azoy Alexander","position":1,"cik":"0001771961","reported_name":"Azoy Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-08-15T20:45:06.000Z","date":"2024-08-13","kind":"sale","planned":true,"acquired":false,"shares":1357,"price":14.97,"value":20314.29,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2024."},{"field":"shares","element":"transactionShares","label":"F2","text":"Consists of 1,357 shares purchased on 5/31/2024 through the Company's Employee Stock Purchase Plan."}],"balance_after":19070,"source":{"system":"sec-edgar","filing":"0001724521-24-000141","document":"wk-form4_1723754700.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000172452124000141/wk-form4_1723754700.xml","form_type":"4"}},{"id":1670966,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":20360,"kind":"person","name":"Azoy Alexander","position":1,"cik":"0001771961","reported_name":"Azoy Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-01-26T00:39:50.000Z","date":"2024-01-23","kind":"grant","planned":false,"acquired":true,"shares":5900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option becomes exercisable in 48 equal monthly installments after January 1, 2024, subject to the Reporting Person's continued service to the Company."}],"balance_after":5900,"derivative":{"exercise_price":15.44,"expiration_date":"2034-01-22","underlying":"Common Stock","underlying_shares":5900},"source":{"system":"sec-edgar","filing":"0001724521-24-000028","document":"wk-form4_1706229580.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000172452124000028/wk-form4_1706229580.xml","form_type":"4"}},{"id":1670965,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":20360,"kind":"person","name":"Azoy Alexander","position":1,"cik":"0001771961","reported_name":"Azoy Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-01-26T00:39:50.000Z","date":"2024-01-23","kind":"grant","planned":false,"acquired":true,"shares":8850,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2024, subject to the Reporting Person's continued service to the Company."}],"balance_after":19070,"source":{"system":"sec-edgar","filing":"0001724521-24-000028","document":"wk-form4_1706229580.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000172452124000028/wk-form4_1706229580.xml","form_type":"4"}},{"id":1700964,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":20360,"kind":"person","name":"Azoy Alexander","position":1,"cik":"0001771961","reported_name":"Azoy Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2023-12-22T21:06:35.000Z","date":"2023-12-20","kind":"disposition_to_issuer","planned":true,"acquired":false,"shares":68,"price":18.21,"value":1238.28,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 30, 2023."}],"balance_after":10220,"source":{"system":"sec-edgar","filing":"0001724521-23-000073","document":"wk-form4_1703279185.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000172452123000073/wk-form4_1703279185.xml","form_type":"4"}},{"id":1703391,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":20360,"kind":"person","name":"Azoy Alexander","position":1,"cik":"0001771961","reported_name":"Azoy Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2023-12-20T21:10:27.000Z","date":"2023-12-19","kind":"disposition_to_issuer","planned":true,"acquired":false,"shares":661,"price":18.09,"value":11957.49,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold by the issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the date of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on January 15, 2021, and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.78 to $18.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":10288,"source":{"system":"sec-edgar","filing":"0001724521-23-000068","document":"wk-form4_1703106610.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000172452123000068/wk-form4_1703106610.xml","form_type":"4"}},{"id":1703390,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":20360,"kind":"person","name":"Azoy Alexander","position":1,"cik":"0001771961","reported_name":"Azoy Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2023-12-20T21:10:27.000Z","date":"2023-12-18","kind":"disposition_to_issuer","planned":true,"acquired":false,"shares":647,"price":17.74,"value":11477.78,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold by the issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the date of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on January 15, 2021, and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.45 to $17.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":10949,"source":{"system":"sec-edgar","filing":"0001724521-23-000068","document":"wk-form4_1703106610.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000172452123000068/wk-form4_1703106610.xml","form_type":"4"}},{"id":1721795,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":20360,"kind":"person","name":"Azoy Alexander","position":1,"cik":"0001771961","reported_name":"Azoy Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2023-12-05T21:28:11.000Z","date":"2023-12-01","kind":"sale","planned":true,"acquired":false,"shares":282,"price":14.95,"value":4215.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 30, 2023."},{"field":"shares","element":"transactionShares","label":"F2","text":"Consists of 282 shares purchased on 11/30/2023 through the Company's Employee Stock Purchase Plan."}],"balance_after":11596,"source":{"system":"sec-edgar","filing":"0001724521-23-000024","document":"wk-form4_1701811666.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000172452123000024/wk-form4_1701811666.xml","form_type":"4"}},{"id":1836385,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":20360,"kind":"person","name":"Azoy Alexander","position":1,"cik":"0001771961","reported_name":"Azoy Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2023-07-05T20:05:39.000Z","date":"2023-07-03","kind":"sale","planned":true,"acquired":false,"shares":1018,"price":20.41,"value":20777.38,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 30, 2023."}],"balance_after":11596,"source":{"system":"sec-edgar","filing":"0001209191-23-040964","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000120919123040964/doc4.xml","form_type":"4"}},{"id":3031276,"issuer":{"id":77428,"kind":"organization","name":"Unity Biotechnology, Inc.","symbol":"UBX"},"owners":[{"id":20360,"kind":"person","name":"Azoy Alexander","position":1,"cik":"0001771961","reported_name":"Azoy Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock, $0.0001 par value","published_at":"2020-09-15T20:56:09.000Z","date":"2020-09-13","kind":"grant","acquired":true,"shares":135000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\") one-third of which vests on September 13, 2021 with the remaining RSUs vesting in equal quarterly installments over a two year period thereafter.   Each RSU represents a contingent right to receive one share of Common Stock of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\") one-third of which vests on September 13, 2021 with the remaining RSUs vesting in equal quarterly installments over a two year period thereafter.   Each RSU represents a contingent right to receive one share of Common Stock of the Issuer."}],"balance_after":135000,"source":{"system":"sec-edgar","filing":"0000899243-20-025180","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1463361/000089924320025180/doc4.xml","form_type":"4"}},{"id":3397369,"issuer":{"id":154554,"kind":"organization","name":"Sienna Biopharmaceuticals, Inc.","symbol":"SNNA"},"owners":[{"id":20360,"kind":"person","name":"Azoy Alexander","position":1,"cik":"0001771961","reported_name":"Azoy Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-10-04T14:10:46.000Z","date":"2019-10-02","kind":"tax_withholding","acquired":false,"shares":2396,"price":0.23,"value":551.08,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares otherwise issuable to the Reporting Person that were withheld to satisfy the Issuer's tax withholding obligation upon settlement of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades in prices ranging from $0.225 to $0.2255 inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":103552,"source":{"system":"sec-edgar","filing":"0001562180-19-005117","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1656328/000156218019005117/primarydocument.xml","form_type":"4"}},{"id":3443549,"issuer":{"id":154554,"kind":"organization","name":"Sienna Biopharmaceuticals, Inc.","symbol":"SNNA"},"owners":[{"id":20360,"kind":"person","name":"Azoy Alexander","position":1,"cik":"0001771961","reported_name":"Azoy Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2019-08-08T16:42:02.000Z","date":"2019-08-06","kind":"grant","acquired":true,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported herein reflect a one-time stock option repricing (the \"Option Repricing\") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934.  Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71.  There have been no other changes to the terms of the relevant options."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction reported herein reflect a one-time stock option repricing (the \"Option Repricing\") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934.  Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71.  There have been no other changes to the terms of the relevant options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Twenty-five percent (25%) of the shares subject to the option vest and become exercisable on October 1,2019, twenty-five percent (25%) of the shares vest and become exercisable on April 1, 2020, and the remaining shares vest and become exercisable in 12 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date."}],"balance_after":20000,"derivative":{"exercise_price":0.71,"expiration_date":"2029-04-01","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001562180-19-004218","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1656328/000156218019004218/primarydocument.xml","form_type":"4"}},{"id":3443548,"issuer":{"id":154554,"kind":"organization","name":"Sienna Biopharmaceuticals, Inc.","symbol":"SNNA"},"owners":[{"id":20360,"kind":"person","name":"Azoy Alexander","position":1,"cik":"0001771961","reported_name":"Azoy Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2019-08-08T16:42:02.000Z","date":"2019-08-06","kind":"grant","acquired":true,"shares":8750,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported herein reflect a one-time stock option repricing (the \"Option Repricing\") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934.  Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71.  There have been no other changes to the terms of the relevant options."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction reported herein reflect a one-time stock option repricing (the \"Option Repricing\") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934.  Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71.  There have been no other changes to the terms of the relevant options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Twenty-five percent (25%) of the shares subject to the option vest and become exercisable on July 1,2019, twenty-five percent (25%) of the shares vest and become exercisable on January 1, 2020, and the remaining shares vest and become exercisable in 12 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date."}],"balance_after":8750,"derivative":{"exercise_price":0.71,"expiration_date":"2029-01-01","underlying":"Common Stock","underlying_shares":8750},"source":{"system":"sec-edgar","filing":"0001562180-19-004218","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1656328/000156218019004218/primarydocument.xml","form_type":"4"}},{"id":3443547,"issuer":{"id":154554,"kind":"organization","name":"Sienna Biopharmaceuticals, Inc.","symbol":"SNNA"},"owners":[{"id":20360,"kind":"person","name":"Azoy Alexander","position":1,"cik":"0001771961","reported_name":"Azoy Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2019-08-08T16:42:02.000Z","date":"2019-08-06","kind":"grant","acquired":true,"shares":8750,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported herein reflect a one-time stock option repricing (the \"Option Repricing\") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934.  Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71.  There have been no other changes to the terms of the relevant options."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction reported herein reflect a one-time stock option repricing (the \"Option Repricing\") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934.  Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71.  There have been no other changes to the terms of the relevant options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Twenty percent (20%) of the shares subject to the option vest and become exercisable upon satisfaction of one performance-based milestone, forty percent (40%) of the shares vest and become exercisable upon satisfaction of a second performance-based milestone, and the remaining forty percent (40%) of the shares vest and become exercisable upon satisfaction of a third performance-based milestone, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date."}],"balance_after":8750,"derivative":{"exercise_price":0.71,"expiration_date":"2029-01-01","underlying":"Common Stock","underlying_shares":8750},"source":{"system":"sec-edgar","filing":"0001562180-19-004218","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1656328/000156218019004218/primarydocument.xml","form_type":"4"}},{"id":3443546,"issuer":{"id":154554,"kind":"organization","name":"Sienna Biopharmaceuticals, Inc.","symbol":"SNNA"},"owners":[{"id":20360,"kind":"person","name":"Azoy Alexander","position":1,"cik":"0001771961","reported_name":"Azoy Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2019-08-08T16:42:02.000Z","date":"2019-08-06","kind":"grant","acquired":true,"shares":5600,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported herein reflect a one-time stock option repricing (the \"Option Repricing\") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934.  Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71.  There have been no other changes to the terms of the relevant options."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction reported herein reflect a one-time stock option repricing (the \"Option Repricing\") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934.  Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71.  There have been no other changes to the terms of the relevant options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Twenty-Five percent (25%) of the shares subject to the option vest and become exercisable on the first anniversary measured from June 1, 2018, and the remaining shares subject to the option vest and become exercisable in 36 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date."}],"balance_after":5600,"derivative":{"exercise_price":0.71,"expiration_date":"2028-06-01","underlying":"Common Stock","underlying_shares":5600},"source":{"system":"sec-edgar","filing":"0001562180-19-004218","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1656328/000156218019004218/primarydocument.xml","form_type":"4"}},{"id":3443545,"issuer":{"id":154554,"kind":"organization","name":"Sienna Biopharmaceuticals, Inc.","symbol":"SNNA"},"owners":[{"id":20360,"kind":"person","name":"Azoy Alexander","position":1,"cik":"0001771961","reported_name":"Azoy Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2019-08-08T16:42:02.000Z","date":"2019-08-06","kind":"grant","acquired":true,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported herein reflect a one-time stock option repricing (the \"Option Repricing\") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934.  Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71.  There have been no other changes to the terms of the relevant options."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction reported herein reflect a one-time stock option repricing (the \"Option Repricing\") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934.  Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71.  There have been no other changes to the terms of the relevant options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Twenty-five percent (25%) of the shares subject to the option vest and become exercisable on the first anniversary measured from December 1, 2017, and the remaining shares subject to the option vest and become exercisable in 36 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date."}],"balance_after":25000,"derivative":{"exercise_price":0.71,"expiration_date":"2027-12-01","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001562180-19-004218","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1656328/000156218019004218/primarydocument.xml","form_type":"4"}},{"id":3443544,"issuer":{"id":154554,"kind":"organization","name":"Sienna Biopharmaceuticals, Inc.","symbol":"SNNA"},"owners":[{"id":20360,"kind":"person","name":"Azoy Alexander","position":1,"cik":"0001771961","reported_name":"Azoy Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2019-08-08T16:42:02.000Z","date":"2019-08-06","kind":"disposition_to_issuer","acquired":false,"shares":8750,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported herein reflect a one-time stock option repricing (the \"Option Repricing\") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934.  Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71.  There have been no other changes to the terms of the relevant options."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction reported herein reflect a one-time stock option repricing (the \"Option Repricing\") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934.  Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71.  There have been no other changes to the terms of the relevant options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Twenty-five percent (25%) of the shares subject to the option vest and become exercisable on July 1,2019, twenty-five percent (25%) of the shares vest and become exercisable on January 1, 2020, and the remaining shares vest and become exercisable in 12 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date."}],"balance_after":0,"derivative":{"exercise_price":2.32,"expiration_date":"2029-01-01","underlying":"Common Stock","underlying_shares":8750},"source":{"system":"sec-edgar","filing":"0001562180-19-004218","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1656328/000156218019004218/primarydocument.xml","form_type":"4"}},{"id":3443543,"issuer":{"id":154554,"kind":"organization","name":"Sienna Biopharmaceuticals, Inc.","symbol":"SNNA"},"owners":[{"id":20360,"kind":"person","name":"Azoy Alexander","position":1,"cik":"0001771961","reported_name":"Azoy Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2019-08-08T16:42:02.000Z","date":"2019-08-06","kind":"disposition_to_issuer","acquired":false,"shares":8750,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported herein reflect a one-time stock option repricing (the \"Option Repricing\") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934.  Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71.  There have been no other changes to the terms of the relevant options."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction reported herein reflect a one-time stock option repricing (the \"Option Repricing\") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934.  Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71.  There have been no other changes to the terms of the relevant options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Twenty percent (20%) of the shares subject to the option vest and become exercisable upon satisfaction of one performance-based milestone, forty percent (40%) of the shares vest and become exercisable upon satisfaction of a second performance-based milestone, and the remaining forty percent (40%) of the shares vest and become exercisable upon satisfaction of a third performance-based milestone, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date."}],"balance_after":0,"derivative":{"exercise_price":2.32,"expiration_date":"2029-01-01","underlying":"Common Stock","underlying_shares":8750},"source":{"system":"sec-edgar","filing":"0001562180-19-004218","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1656328/000156218019004218/primarydocument.xml","form_type":"4"}},{"id":3443542,"issuer":{"id":154554,"kind":"organization","name":"Sienna Biopharmaceuticals, Inc.","symbol":"SNNA"},"owners":[{"id":20360,"kind":"person","name":"Azoy Alexander","position":1,"cik":"0001771961","reported_name":"Azoy Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2019-08-08T16:42:02.000Z","date":"2019-08-06","kind":"disposition_to_issuer","acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported herein reflect a one-time stock option repricing (the \"Option Repricing\") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934.  Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71.  There have been no other changes to the terms of the relevant options."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction reported herein reflect a one-time stock option repricing (the \"Option Repricing\") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934.  Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71.  There have been no other changes to the terms of the relevant options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Twenty-five percent (25%) of the shares subject to the option vest and become exercisable on October 1,2019, twenty-five percent (25%) of the shares vest and become exercisable on April 1, 2020, and the remaining shares vest and become exercisable in 12 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date."}],"balance_after":0,"derivative":{"exercise_price":2.37,"expiration_date":"2029-04-01","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001562180-19-004218","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1656328/000156218019004218/primarydocument.xml","form_type":"4"}},{"id":3443541,"issuer":{"id":154554,"kind":"organization","name":"Sienna Biopharmaceuticals, Inc.","symbol":"SNNA"},"owners":[{"id":20360,"kind":"person","name":"Azoy Alexander","position":1,"cik":"0001771961","reported_name":"Azoy Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2019-08-08T16:42:02.000Z","date":"2019-08-06","kind":"disposition_to_issuer","acquired":false,"shares":5600,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported herein reflect a one-time stock option repricing (the \"Option Repricing\") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934.  Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71.  There have been no other changes to the terms of the relevant options."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction reported herein reflect a one-time stock option repricing (the \"Option Repricing\") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934.  Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71.  There have been no other changes to the terms of the relevant options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Twenty-Five percent (25%) of the shares subject to the option vest and become exercisable on the first anniversary measured from June 1, 2018, and the remaining shares subject to the option vest and become exercisable in 36 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date."}],"balance_after":0,"derivative":{"exercise_price":15.08,"expiration_date":"2028-06-01","underlying":"Common Stock","underlying_shares":5600},"source":{"system":"sec-edgar","filing":"0001562180-19-004218","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1656328/000156218019004218/primarydocument.xml","form_type":"4"}},{"id":3443540,"issuer":{"id":154554,"kind":"organization","name":"Sienna Biopharmaceuticals, Inc.","symbol":"SNNA"},"owners":[{"id":20360,"kind":"person","name":"Azoy Alexander","position":1,"cik":"0001771961","reported_name":"Azoy Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2019-08-08T16:42:02.000Z","date":"2019-08-06","kind":"disposition_to_issuer","acquired":false,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported herein reflect a one-time stock option repricing (the \"Option Repricing\") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934.  Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71.  There have been no other changes to the terms of the relevant options."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction reported herein reflect a one-time stock option repricing (the \"Option Repricing\") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934.  Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71.  There have been no other changes to the terms of the relevant options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Twenty-five percent (25%) of the shares subject to the option vest and become exercisable on the first anniversary measured from December 1, 2017, and the remaining shares subject to the option vest and become exercisable in 36 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date."}],"balance_after":0,"derivative":{"exercise_price":20.19,"expiration_date":"2027-12-01","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001562180-19-004218","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1656328/000156218019004218/primarydocument.xml","form_type":"4"}},{"id":3443539,"issuer":{"id":154554,"kind":"organization","name":"Sienna Biopharmaceuticals, Inc.","symbol":"SNNA"},"owners":[{"id":20360,"kind":"person","name":"Azoy Alexander","position":1,"cik":"0001771961","reported_name":"Azoy Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-08-08T16:42:02.000Z","date":"2019-08-06","kind":"grant","acquired":true,"shares":70000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Award of restricted stock units (\"RSUs\") granted under the Issuer's 2017 Incentive Award Plan.  Each RSU entitles the Reporting Person to receive one share of Issuer common stock upon vesting.  The award vests as to fifty percent (50%) of the total number of RSUs on February 6, 2020, twenty-five percent (25%) of the total number of RSUs on August 6, 2020, and the remaining twenty-five percent (25%) of the total number of RSUs on February 6, 2021, in each case, subject to the Reporting Person's continued employment or service relationship with the Issuer through the applicable vesting date."}],"balance_after":105948,"source":{"system":"sec-edgar","filing":"0001562180-19-004218","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1656328/000156218019004218/primarydocument.xml","form_type":"4"}},{"id":3468067,"issuer":{"id":154554,"kind":"organization","name":"Sienna Biopharmaceuticals, Inc.","symbol":"SNNA"},"owners":[{"id":20360,"kind":"person","name":"Azoy Alexander","position":1,"cik":"0001771961","reported_name":"Azoy Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-07-03T13:36:46.000Z","date":"2019-07-02","kind":"tax_withholding","acquired":false,"shares":1552,"price":0.76,"value":1179.52,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares otherwise issuable to the Reporting Person that were withheld to satisfy the Issuer's tax withholding obligation upon settlement of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades in prices ranging from $0.72 to $0.83, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":35948,"source":{"system":"sec-edgar","filing":"0001562180-19-003849","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1656328/000156218019003849/primarydocument.xml","form_type":"4"}},{"id":3565029,"issuer":{"id":154554,"kind":"organization","name":"Sienna Biopharmaceuticals, Inc.","symbol":"SNNA"},"owners":[{"id":20360,"kind":"person","name":"Azoy Alexander","position":1,"cik":"0001771961","reported_name":"Azoy Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2019-04-03T17:44:03.000Z","date":"2019-04-01","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Twenty-five percent (25%) of the shares subject to the option vest and become exercisable on October 1, 2019, twenty-five percent (25%) of the shares vest and become exercisable on April 1, 2020, and the remaining shares vest and become exercisable in 12 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date."}],"balance_after":20000,"derivative":{"exercise_price":2.37,"expiration_date":"2029-04-01","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001562180-19-002196","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1656328/000156218019002196/primarydocument.xml","form_type":"4"}},{"id":3565028,"issuer":{"id":154554,"kind":"organization","name":"Sienna Biopharmaceuticals, Inc.","symbol":"SNNA"},"owners":[{"id":20360,"kind":"person","name":"Azoy Alexander","position":1,"cik":"0001771961","reported_name":"Azoy Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-04-03T17:44:03.000Z","date":"2019-04-01","kind":"grant","acquired":true,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Award of restricted stock units (\"RSUs\") granted under the Issuer's 2017 Incentive Award Plan.  Each RSU entitles the Reporting Person to receive one share of Issuer's common stock upon vesting.  The award vests as to twenty-five percent (25%) of the total number of RSUs on October 1, 2019, twenty-five percent (25%)  of the total number of RSUs on April 1, 2020, and the remaining fifty percent (50%) of the total number of RSUs on the second anniversary, in each case, subject to the Reporting Person's continued employment or service relationship with the Issuer through the applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 17,500 shares of the Issuer's common stock underlying the RSUs awarded."}],"balance_after":37500,"source":{"system":"sec-edgar","filing":"0001562180-19-002196","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1656328/000156218019002196/primarydocument.xml","form_type":"4"}}]}